Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
. Free PMC article.
Using DNA sequencing data to quantify T cell fraction and therapy response.
Bentham R, Litchfield K, Watkins TBK, Lim EL, Rosenthal R, Martínez-Ruiz C, Hiley CT, Bakir MA, Salgado R, Moore DA, Jamal-Hanjani M; TRACERx Consortium, Swanton C, McGranahan N.
.
Item in Clipboard
![top](data:image/svg+xml,%3Csvg%20xmlns="http://www.w3.org/2000/svg"%20width="16"%20height="16"%3E%3Crect%20fill-opacity="0"/%3E%3C/svg%3E "top")
